Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBI as a predictive factor for tolerability of adjuvant S-1 after gastrectomy in stage II/III gastric cancer
jRCT1090220373
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tegafur in gastric cancer (GC), sponsored by None.
02
Drugs
tegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCT1090220373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220373.